查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961399

細胞表面標誌物檢測市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

Cell Surface Markers Detection Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球細胞表面標誌物檢測市場預計將從 2025 年的 104.6 億美元成長到 2031 年的 159.2 億美元，複合年成長率為 7.25%。

該領域主要集中於利用專用試劑和分析儀器檢測細胞膜上的抗原和蛋白質，以用於診斷和研究目的。推動該行業發展的主要動力是慢性疾病（尤其是癌症）的日益普遍。準確的免疫表現型分析對於有效的疾病管理至關重要。此外，向個人化醫療的轉變——這種轉變高度依賴生物標記分析來制定個人化的治療策略——也加速了該行業的發展。美國癌症協會估計，到2025年，美國將新增2,041,910例癌症病例，這項數據凸顯了可靠的檢測技術對於支持早期診斷和治療計畫的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 104.6億美元
市場規模：2031年 159.2億美元
複合年成長率：2026-2031年 7.25%
成長最快的細分市場 流式細胞技術
最大的市場 北美洲

儘管市場前景廣闊，但先進設備所需的龐大資本投入仍構成重大障礙。購買流式細胞技術系統和特異性抗體的高昂成本會有效阻礙預算有限地區的普及。此外，解讀實驗數據的複雜性需要專業人員，這進一步限制了小規模實驗室的應用。這些經濟和營運方面的障礙可能會減緩檢測解決方案的推廣，尤其是在新興醫療基礎設施可能缺乏支援先進技術的資源的情況下。

市場促進因素

精準醫療和標靶治療的日益普及是推動市場成長的主要動力，也因此對可靠的細胞表面標誌物檢測產生了強勁的需求，以支持患者分層和治療監測。研究人員和臨床醫生越來越依賴免疫表現型分析來識別特定的抗原，例如HER2和PD-1，這些抗原可以作為新型免疫療法和生物製藥的標靶。這種對基於生物標記的干涉措施的依賴，推動了對特定抗體和檢測試劑盒的需求，而這些抗體和試劑盒對於確定哪些患者適合接受這些先進療法至關重要。例如，百時美施貴寶公司在2025年2月報告稱，其PD-1表面蛋白靶向免疫腫瘤療法Opdivo在2024年的銷售額達到了93億美元，這體現了這一趨勢的商業性影響。這表明精準的標誌物識別與高價值標靶治療的成功之間存在著至關重要的聯繫。

此外，製藥公司在生物製劑和細胞療法領域不斷增加的研發投入正在推動產業成長，同時也拓展了藥物研發領域的應用範圍。對細胞表現型進行廣泛篩檢對於檢驗新型候選藥物至關重要，這也推動了先進檢測試劑和流式細胞技術的應用。羅氏控股公司在2025年1月發布的2024年度報告中指出，其核心研發投入達到130.4億瑞士法郎，凸顯了依賴細胞分析的治療創新領域巨大的資本投入。這種積極的研究也直接惠及診斷技術供應商。例如，賽默飛世爾科技公司在2025年1月發布的報告顯示，其全年銷售額達428.8億美元，反映了生命科學服務和工具的巨大需求。

市場挑戰

全球細胞表面標誌物檢測市場成長的主要障礙之一是購買先進設備所需的高昂資本成本。螢光活化細胞分選和流式細胞技術等技術對於準確鑑定表面蛋白至關重要，但購買這些設備需要大量投資。對於資金有限的研究機構和小規模學術實驗室而言，這筆負擔尤其沉重。除了初始投資成本外，特異性抗體和系統維護的持續費用也顯著增加了整體擁有成本。因此，許多機構被迫限制檢測平台的採購或推遲關鍵設備的更新，這直接阻礙了這些技術的廣泛應用。

這些經濟限制因素因近期聯邦政府削減撥款而加劇，而聯邦政府的撥款歷來用於支持此類研究所需的基礎設施。津貼減少導致各機構無法獲得投資資本密集系統所需的流動資金。根據美國醫學院協會 (AAMC) 2025 年的數據，美國國立衛生研究院 (NIH) 取消了約 2282 項津貼，總額達 38 億美元，給教學醫院和醫學院帶來了沉重的財務負擔。如此大幅度的削減直接阻礙了市場成長，迫使研究中心降低購買昂貴設備的優先順序。如果沒有穩定的財政支持來抵銷這些高昂的資本成本，有效打入預算緊張的市場將會十分困難。

市場趨勢

將自動化和人工智慧整合到診斷工作流程中，透過提高細胞標記分析的可重複性和效率，正在從根本上改變市場格局。隨著高通量實驗室處理日益成長的樣本量，人工智慧驅動的設門軟體和自動化樣本製備系統對於標準化免疫表現型分析結果和減少人為誤差至關重要。這項技術進步能夠快速處理現代疾病監測所需的複雜資料集，並直接影響下一代平台的採購決策。這些能力的策略重要性體現在產業領導者的績效中。例如，貝克頓·迪金森公司（Becton, Dickinson and Company）公佈截至2025年2月的會計年度季度收入約為52億美元，並指出其診斷解決方案部門在實驗室自動化方面的卓越實力是其成功的關鍵促進因素。

同時，用於高參數多重分析的頻譜流式細胞技術儀正迅速發展。這主要是由於在詳細的分析研究中需要分解重疊的螢光訊號。與傳統的基於補償的技術不同，頻譜技術能夠分離螢光染料的完整發射光譜，使研究人員能夠在單一試管中檢測到更多細胞表面標誌物。這項功能在免疫腫瘤學研究中尤其重要，因為該領域需要高解析度來表徵稀有細胞亞群。專用儀器的快速成長凸顯了市場對這項先進技術的強勁需求。根據Cytek Biosciences公司2025年2月發布的財務報告，該公司僅在2024年就安裝了667台新的頻譜分析，使其全球安裝量達到3034台。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：細胞表面標誌物檢測的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（流式細胞技術、血液分析儀、細胞影像系統、試劑/試劑盒、其他）
    • 按應用領域（疾病診斷/鑑定、研究/藥物發現、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美細胞表面標誌物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲細胞表面標誌物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區細胞表面標誌物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲細胞表面標誌物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美細胞表面標誌物檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球細胞表面標誌物檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Becton, Dickinson and Company
  • Nihon Kohden Corporation
  • Sysmex Corporation
  • Thermo Fisher Scientific inc.
  • Nexcelom Bioscience LLC
  • Beckman Coulter Inc.
  • Qiagen NV
  • IVD Medical Holding Limited
  • Agilent Technologies Inc.
  • Luminex Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 20086

The Global Cell Surface Markers Detection Market is projected to expand from a valuation of USD 10.46 Billion in 2025 to USD 15.92 Billion by 2031, reflecting a compound annual growth rate of 7.25%. This sector primarily focuses on using specialized reagents and analytical instruments to detect antigens or proteins located on the cellular plasma membrane for both diagnostic and research purposes. A major force propelling this industry is the rising prevalence of chronic conditions, particularly cancer, which necessitates accurate immunophenotyping for effective disease management. Furthermore, the industry is being accelerated by the transition toward personalized medicine, which relies heavily on biomarker analysis to customize therapeutic strategies. Highlighting this urgency, the American Cancer Society estimates that there will be 2,041,910 new cancer cases in the United States in 2025, a statistic that emphasizes the vital need for dependable detection technologies to aid in early diagnosis and treatment formulation.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 10.46 Billion
Market Size 2031USD 15.92 Billion
CAGR 2026-20317.25%
Fastest Growing SegmentFlow Cytometry
Largest MarketNorth America

Despite these growth prospects, the market encounters substantial obstacles related to the significant capital investment required for advanced instrumentation. The high expense associated with purchasing flow cytometry systems and specific antibodies can effectively block adoption in regions with limited budgets. Moreover, the complexity of interpreting the resulting data necessitates specialized personnel, which further restricts accessibility in smaller laboratory settings. Together, these economic and operational barriers threaten to slow the widespread integration of detection solutions, particularly within emerging healthcare infrastructures that may lack the resources to support such advanced technologies.

Market Driver

The escalating adoption of precision medicine and targeted therapies serves as a primary engine for market expansion, creating a strong demand for reliable cell surface marker detection to support patient stratification and treatment monitoring. Both researchers and clinicians are increasingly dependent on immunophenotyping to pinpoint specific antigens, such as HER2 or PD-1, which act as targets for new immunotherapies and biologic drugs. This reliance on biomarker-guided interventions drives the consumption of specific antibodies and assay kits essential for determining which patients are eligible for these sophisticated treatments. As an example of this trend's commercial impact, Bristol Myers Squibb reported in February 2025 that their immuno-oncology therapy Opdivo, which targets the PD-1 surface protein, achieved $9.3 billion in sales during 2024, illustrating the essential connection between precise marker identification and the success of high-value targeted regimens.

Additionally, the industry is being propelled by expanding applications within pharmaceutical research and development, as companies increase their investment in creating biologics and cell-based therapies. Validating new drug candidates necessitates the extensive screening of cellular phenotypes, which in turn drives the acquisition of advanced detection reagents and flow cytometry instruments. In its 2024 Annual Report released in January 2025, Roche Holding AG noted that its core research and development investments hit CHF 13.04 billion, highlighting the immense capital commitment toward therapeutic innovations that depend on cellular analysis. This robust research activity directly advantages diagnostic technology providers; for instance, Thermo Fisher Scientific Inc. reported full-year revenue of $42.88 billion in January 2025, reflecting the massive scale of demand for life sciences services and tools.

Market Challenge

A significant impediment to the growth of the Global Cell Surface Markers Detection Market is the high capital cost required for advanced instrumentation. While technologies like fluorescence-activated cell sorting and flow cytometry are critical for the accurate identification of surface proteins, procuring this machinery demands a heavy financial commitment. This burden is especially restrictive for research facilities and smaller academic laboratories that operate with limited funding. When the initial acquisition price is combined with ongoing expenses for specific antibodies and system maintenance, the total cost of ownership becomes a major deterrent. As a result, many institutions are compelled to limit their purchase of detection platforms or postpone essential equipment upgrades, which directly stifles the broader uptake of these technologies.

These economic constraints are further intensified by recent reductions in federal funding, which has traditionally supported the infrastructure necessary for this type of research. A decrease in grant availability restricts the liquidity institutions require to invest in capital-intensive systems. According to data from the Association of American Medical Colleges in 2025, the cancellation of approximately 2,282 National Institutes of Health grants, amounting to $3.8 billion, has placed significant financial strain on teaching hospitals and medical schools. Such drastic cuts directly impede market growth, as research centers are forced to deprioritize the purchase of expensive instruments. Without consistent financial backing to offset these high capital costs, the market faces difficulties in effectively penetrating sectors that are constrained by tight budgets.

Market Trends

The incorporation of automation and artificial intelligence into diagnostic workflows is fundamentally transforming the market by improving the reproducibility and efficiency of cell marker analysis. As laboratories dealing with high throughputs encounter growing sample volumes, AI-driven gating software and automated sample preparation systems are becoming indispensable for standardizing immunophenotyping results and mitigating manual errors. This technological evolution enables the rapid processing of the complex datasets necessary for modern disease monitoring, thereby directly shaping purchasing decisions regarding next-generation platforms. The strategic importance of these capabilities is reflected in the performance of key industry leaders; for example, Becton, Dickinson and Company reported quarterly revenue of roughly $5.2 billion in February 2025, citing specific strength in Lab Automation within its Diagnostic Solutions segment as a primary factor in this operational success.

Concurrently, the shift toward spectral flow cytometry for high-parameter multiplexing is gaining considerable momentum, fueled by the necessity to resolve overlapping fluorescence signals in deep profiling studies. In contrast to traditional compensation-based techniques, spectral technology unmixes the complete emission signature of fluorochromes, allowing researchers to detect a greater number of cell surface markers within a single tube. This capability is especially vital for immuno-oncology research, where the characterization of rare cell subsets requires granular resolution. The market's strong demand for this advanced technology is evidenced by the rapid growth of specialized instrument bases; according to Cytek Biosciences' financial results released in February 2025, the company expanded its global footprint to 3,034 instruments, having installed 667 new spectral analysis units in 2024 alone.

Key Market Players

  • Becton, Dickinson and Company
  • Nihon Kohden Corporation
  • Sysmex Corporation
  • Thermo Fisher Scientific inc.
  • Nexcelom Bioscience LLC
  • Beckman Coulter Inc.
  • Qiagen NV
  • IVD Medical Holding Limited
  • Agilent Technologies Inc.
  • Luminex Corporation

Report Scope

In this report, the Global Cell Surface Markers Detection Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Surface Markers Detection Market, By Product

  • Flow Cytometry
  • Hematology Analyzers
  • Cell Imaging Systems
  • Reagents and Kits
  • Other

Cell Surface Markers Detection Market, By Application

  • Disease Diagnosis And Identifications
  • Research And Drug Discovery
  • Others

Cell Surface Markers Detection Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Surface Markers Detection Market.

Available Customizations:

Global Cell Surface Markers Detection Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Surface Markers Detection Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Flow Cytometry, Hematology Analyzers, Cell Imaging Systems, Reagents and Kits, Other)
    • 5.2.2. By Application (Disease Diagnosis And Identifications, Research And Drug Discovery, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Cell Surface Markers Detection Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell Surface Markers Detection Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Cell Surface Markers Detection Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Cell Surface Markers Detection Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Cell Surface Markers Detection Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell Surface Markers Detection Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. France Cell Surface Markers Detection Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Cell Surface Markers Detection Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Cell Surface Markers Detection Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Cell Surface Markers Detection Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Cell Surface Markers Detection Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Cell Surface Markers Detection Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Cell Surface Markers Detection Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Cell Surface Markers Detection Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Cell Surface Markers Detection Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Cell Surface Markers Detection Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. Middle East & Africa Cell Surface Markers Detection Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Cell Surface Markers Detection Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Cell Surface Markers Detection Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Cell Surface Markers Detection Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. South America Cell Surface Markers Detection Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cell Surface Markers Detection Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Cell Surface Markers Detection Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Cell Surface Markers Detection Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Cell Surface Markers Detection Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Becton, Dickinson and Company
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Nihon Kohden Corporation
  • 15.3. Sysmex Corporation
  • 15.4. Thermo Fisher Scientific inc.
  • 15.5. Nexcelom Bioscience LLC
  • 15.6. Beckman Coulter Inc.
  • 15.7. Qiagen NV
  • 15.8. IVD Medical Holding Limited
  • 15.9. Agilent Technologies Inc.
  • 15.10. Luminex Corporation

16. Strategic Recommendations

17. About Us & Disclaimer